Which side effects were most frequently reported in virologically suppressed patients who switched to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Gilead?

In 48-week Phase III study GS-US-264-0106, virologically suppressed patients switching from a ritonavir-boosted PI regimen to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Gilead most frequently reported fatigue (3%), diarrhoea (3%), nausea (2%) and insomnia (2%) as adverse reactions considered possibly or probably treatment-related.